Page last updated: 2024-10-24

NAD+- protein-cysteine ADP-ribosyltransferase activity

Definition

Target type: molecularfunction

Catalysis of the reaction: L-cysteinyl-[protein] + NAD+ = H+ + nicotinamide + S-(ADP-D-ribosyl)-L-cysteinyl-[protein]. [PMID:25043379, RHEA:56612]

NAD+-protein-cysteine ADP-ribosyltransferase activity catalyzes the transfer of ADP-ribose from NAD+ to a cysteine residue on a target protein. This reaction involves the cleavage of the nicotinamide moiety from NAD+, leaving the ADP-ribose moiety to be attached to the cysteine residue. This process is known as ADP-ribosylation. ADP-ribosylation can have various effects on target proteins, including altering their activity, localization, and interactions with other proteins. ADP-ribosyltransferases are involved in a wide range of cellular processes, including signal transduction, DNA repair, and immune response. For example, some ADP-ribosyltransferases are involved in the regulation of cellular stress responses, while others play a role in the immune system by modifying the activity of immune cells. The activity of ADP-ribosyltransferases can be regulated by a variety of factors, including post-translational modifications, protein-protein interactions, and the availability of NAD+. Dysregulation of ADP-ribosyltransferase activity can lead to a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.'
"

Proteins (4)

ProteinDefinitionTaxonomy
Protein mono-ADP-ribosyltransferase PARP11A protein mono-ADP-ribosyltransferase PARP11 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9NR21]Homo sapiens (human)
Protein mono-ADP-ribosyltransferase PARP12A protein mono-ADP-ribosyltransferase PARP12 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9H0J9]Homo sapiens (human)
Protein mono-ADP-ribosyltransferase PARP8A protein mono-ADP-ribosyltransferase PARP8 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8N3A8]Homo sapiens (human)
Protein mono-ADP-ribosyltransferase PARP6A protein mono-ADP-ribosyltransferase PARP6 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q2NL67]Homo sapiens (human)

Compounds (10)

CompoundDefinitionClassesRoles
pj-34PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties.phenanthridines;
secondary carboxamide;
tertiary amino compound
angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent
4-Methoxybenzamidebenzamides
3,4-dihydro-5-methyl-1(2h)-isoquinolinone3,4-dihydro-5-methyl-1(2H)-isoquinolinone: structure given in first sourceisoquinolines
1-oxo-1,2,3,4-tetrahydroisoquinoline1-oxo-1,2,3,4-tetrahydroisoquinoline: structure given in first source
rucaparibAG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first sourceazepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound
antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
veliparibbenzimidazolesEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
olaparibcyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines
antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
niraparibniraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy.

niraparib: structure in first source
2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamideantineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
radiosensitizing agent
xav939XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.

XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source
(trifluoromethyl)benzenes;
thiopyranopyrimidine
tankyrase inhibitor
bmn 673talazoparib: inhibits both PARP1 and PARP2; structure in first source